tiprankstipranks
Merck & Company (MRK)
NYSE:MRK
US Market
MRK
Merck & Company
RESEARCH TOOLSreports
Want to see MRK full AI Analyst Report?

Merck & Company (MRK) Stock Forecast & Price Target

14,873 Followers
See the Price Targets and Ratings of:

MRK Analyst Ratings

Moderate Buy
19Ratings
Moderate Buy
13 Buy
6 Hold
0 Sell
Based on 19 analysts giving stock ratings to
Merck
& Company
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

MRK Stock 12 Month Forecast

Average Price Target

$136.81
▲(14.90% Upside)
Based on 19 Wall Street analysts offering 12 month price targets for Merck & Company in the last 3 months. The average price target is $136.81 with a high forecast of $179.00 and a low forecast of $112.00. The average price target represents a 14.90% change from the last price of $119.07.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"72":"$72","99":"$99","126":"$126","153":"$153","180":"$180"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":179,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$179.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":136.8125,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$136.81</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":112,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$112.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[72,99,126,153,180],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,114.347,119.3203076923077,124.29361538461538,129.26692307692306,134.24023076923078,139.21353846153846,144.18684615384615,149.16015384615383,154.13346153846155,159.10676923076923,164.08007692307692,169.05338461538463,174.02669230769231,{"y":179,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,114.347,116.07511538461537,117.80323076923077,119.53134615384614,121.25946153846154,122.98757692307692,124.71569230769231,126.44380769230769,128.17192307692306,129.90003846153846,131.62815384615385,133.35626923076924,135.0843846153846,{"y":136.8125,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,114.347,114.16646153846153,113.98592307692307,113.80538461538461,113.62484615384615,113.44430769230769,113.26376923076923,113.08323076923077,112.9026923076923,112.72215384615384,112.54161538461538,112.36107692307692,112.18053846153846,{"y":112,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":73.051,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":79.163,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 29, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":76.724,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":81.398,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":88.075,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":84.02,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":99.509,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":103.74,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":111.732,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":119.656,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":119.977,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":111.359,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 50,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":114.347,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$179.00Average Price Target$136.81Lowest Price Target$112.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Barclays Analyst forecast on MRK
Emily Field
Barclays
Barclays
$140
Buy
17.58%
Upside
Reiterated
06/26/26
Barclays Sticks to Their Buy Rating for Merck & Company (MRK)
Citi Analyst forecast on MRK
Geoff Meacham
Citi
Citi
$125
Hold
4.98%
Upside
Reiterated
06/23/26
Citi Keeps Their Hold Rating on Merck & Company (MRK)
BMO Capital Analyst forecast on MRK
Evan Seigerman
BMO Capital
BMO Capital
$135
Buy
13.38%
Upside
Reiterated
06/23/26
BMO Capital Keeps Their Buy Rating on Merck & Company (MRK)
Scotiabank Analyst forecast on MRK
Louise Chen
Scotiabank
Scotiabank
$136
Buy
14.22%
Upside
Reiterated
06/23/26
Scotiabank Reaffirms Their Buy Rating on Merck & Company (MRK)
Berenberg Bank Analyst forecast on MRK
Luisa Hector
Berenberg Bank
Berenberg Bank
$115→$125
Hold
4.98%
Upside
Reiterated
06/22/26
Berenberg Bank Keeps Their Hold Rating on Merck & Company (MRK)
Bernstein Analyst forecast on MRK
Courtney Breen
Bernstein
Bernstein
―
Hold
―
Reiterated
06/09/26
Analysts Offer Insights on Healthcare Companies: 10x Genomics (NASDAQ: TXG), Zevra Therapeutics (NASDAQ: ZVRA) and Merck & Company (NYSE: MRK)
Wells Fargo Analyst forecast on MRK
Mohit Bansal
Wells Fargo
Wells Fargo
$178→$145
Buy
21.78%
Upside
Reiterated
06/08/26
Wells Fargo Keeps Their Buy Rating on Merck & Company (MRK)
Bank of America Securities Analyst forecast on MRK
Jason Gerberry
Bank of America Securities
Bank of America Securities
$130
Buy
9.18%
Upside
Reiterated
06/02/26
Merck’s Lung Cancer Strategy and Next-Gen PD-1/VEGF Pipeline Underpin Buy Rating, $130 Price Target Reiterated
Guggenheim Analyst forecast on MRK
Vamil Divan
Guggenheim
Guggenheim
$140
Buy
17.58%
Upside
Reiterated
06/02/26
Merck & Company (MRK) Receives a Buy from Guggenheim
Goldman Sachs Analyst forecast on MRK
Asad Haider
Goldman Sachs
Goldman Sachs
$133→$137
Buy
15.06%
Upside
Reiterated
06/02/26
Goldman Sachs Reaffirms Their Buy Rating on Merck & Company (MRK)
UBS Analyst forecast on MRK
Michael Yee
UBS
UBS
$145
Buy
21.78%
Upside
Reiterated
06/02/26
Merck & Company (MRK) Receives a Buy from UBS
RBC Capital Analyst forecast on MRK
Trung Huynh
RBC Capital
RBC Capital
―
Buy
―
Reiterated
05/21/26
Analysts Are Bullish on These Healthcare Stocks: Regeneron (REGN), Merck & Company (MRK)
Jefferies Analyst forecast on MRK
Unknown Analyst
Jefferies
Not Ranked
Jefferies
$138
Buy
15.90%
Upside
Reiterated
05/19/26
Jefferies Reaffirms Their Buy Rating on Merck & Company (MRK)
Argus Research Analyst forecast on MRK
Jasper Hellweg
Argus Research
Argus Research
$130
Buy
9.18%
Upside
Reiterated
05/08/26
Argus Research Remains a Buy on Merck & Company (MRK)
Erste Group Analyst forecast on MRK
Hans Engel
Erste Group
Erste Group
―
Hold
―
Reiterated
05/05/26
Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (NASDAQ: AXSM), Vertex Pharmaceuticals (NASDAQ: VRTX) and Merck & Company (NYSE: MRK)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Barclays Analyst forecast on MRK
Emily Field
Barclays
Barclays
$140
Buy
17.58%
Upside
Reiterated
06/26/26
Barclays Sticks to Their Buy Rating for Merck & Company (MRK)
Citi Analyst forecast on MRK
Geoff Meacham
Citi
Citi
$125
Hold
4.98%
Upside
Reiterated
06/23/26
Citi Keeps Their Hold Rating on Merck & Company (MRK)
BMO Capital Analyst forecast on MRK
Evan Seigerman
BMO Capital
BMO Capital
$135
Buy
13.38%
Upside
Reiterated
06/23/26
BMO Capital Keeps Their Buy Rating on Merck & Company (MRK)
Scotiabank Analyst forecast on MRK
Louise Chen
Scotiabank
Scotiabank
$136
Buy
14.22%
Upside
Reiterated
06/23/26
Scotiabank Reaffirms Their Buy Rating on Merck & Company (MRK)
Berenberg Bank Analyst forecast on MRK
Luisa Hector
Berenberg Bank
Berenberg Bank
$115→$125
Hold
4.98%
Upside
Reiterated
06/22/26
Berenberg Bank Keeps Their Hold Rating on Merck & Company (MRK)
Bernstein Analyst forecast on MRK
Courtney Breen
Bernstein
Bernstein
―
Hold
―
Reiterated
06/09/26
Analysts Offer Insights on Healthcare Companies: 10x Genomics (NASDAQ: TXG), Zevra Therapeutics (NASDAQ: ZVRA) and Merck & Company (NYSE: MRK)
Wells Fargo Analyst forecast on MRK
Mohit Bansal
Wells Fargo
Wells Fargo
$178→$145
Buy
21.78%
Upside
Reiterated
06/08/26
Wells Fargo Keeps Their Buy Rating on Merck & Company (MRK)
Bank of America Securities Analyst forecast on MRK
Jason Gerberry
Bank of America Securities
Bank of America Securities
$130
Buy
9.18%
Upside
Reiterated
06/02/26
Merck’s Lung Cancer Strategy and Next-Gen PD-1/VEGF Pipeline Underpin Buy Rating, $130 Price Target Reiterated
Guggenheim Analyst forecast on MRK
Vamil Divan
Guggenheim
Guggenheim
$140
Buy
17.58%
Upside
Reiterated
06/02/26
Merck & Company (MRK) Receives a Buy from Guggenheim
Goldman Sachs Analyst forecast on MRK
Asad Haider
Goldman Sachs
Goldman Sachs
$133→$137
Buy
15.06%
Upside
Reiterated
06/02/26
Goldman Sachs Reaffirms Their Buy Rating on Merck & Company (MRK)
UBS Analyst forecast on MRK
Michael Yee
UBS
UBS
$145
Buy
21.78%
Upside
Reiterated
06/02/26
Merck & Company (MRK) Receives a Buy from UBS
RBC Capital Analyst forecast on MRK
Trung Huynh
RBC Capital
RBC Capital
―
Buy
―
Reiterated
05/21/26
Analysts Are Bullish on These Healthcare Stocks: Regeneron (REGN), Merck & Company (MRK)
Jefferies Analyst forecast on MRK
Unknown Analyst
Jefferies
Not Ranked
Jefferies
$138
Buy
15.90%
Upside
Reiterated
05/19/26
Jefferies Reaffirms Their Buy Rating on Merck & Company (MRK)
Argus Research Analyst forecast on MRK
Jasper Hellweg
Argus Research
Argus Research
$130
Buy
9.18%
Upside
Reiterated
05/08/26
Argus Research Remains a Buy on Merck & Company (MRK)
Erste Group Analyst forecast on MRK
Hans Engel
Erste Group
Erste Group
―
Hold
―
Reiterated
05/05/26
Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (NASDAQ: AXSM), Vertex Pharmaceuticals (NASDAQ: VRTX) and Merck & Company (NYSE: MRK)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Merck & Company

3 Months
Asad HaiderGoldman Sachs
Success Rate
10/11 ratings generated profit
91%
Average Return
+6.82%
Copying Asad Haider's trades and holding each position for 3 Months would result in 90.91% of your transactions generating a profit, with an average return of +6.82% per trade.
1 Year
Asad HaiderGoldman Sachs
Success Rate
11/11 ratings generated profit
100%
Average Return
+25.11%
Copying Asad Haider's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +25.11% per trade.
2 Years
Asad HaiderGoldman Sachs
Success Rate
11/11 ratings generated profit
100%
Average Return
+25.74%
Copying Asad Haider's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +25.74% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

MRK Analyst Recommendation Trends

Rating
Feb 26
Mar 26
Apr 26
May 26
Jun 26
Strong Buy
0
0
1
1
1
Buy
32
40
44
49
41
Hold
18
22
20
18
18
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
50
62
65
68
60
In the current month, MRK has received 42 Buy Ratings, 18 Hold Ratings, and 0 Sell Ratings. MRK average Analyst price target in the past 3 months is 136.81.
Each month's total comprises the sum of three months' worth of ratings.

MRK Financial Forecast

MRK Earnings Forecast

Next quarter’s earnings estimate for MRK is $2.11 with a range of $1.99 to $2.29. The previous quarter’s EPS was -$1.28. MRK beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year MRK has Performed in-line its overall industry.
Next quarter’s earnings estimate for MRK is $2.11 with a range of $1.99 to $2.29. The previous quarter’s EPS was -$1.28. MRK beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year MRK has Performed in-line its overall industry.

MRK Sales Forecast

Next quarter’s sales forecast for MRK is $16.37B with a range of $15.85B to $17.25B. The previous quarter’s sales results were $16.20B. MRK beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year MRK has Performed in-line its overall industry.
Next quarter’s sales forecast for MRK is $16.37B with a range of $15.85B to $17.25B. The previous quarter’s sales results were $16.20B. MRK beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year MRK has Performed in-line its overall industry.

MRK Stock Forecast FAQ

What is MRK’s average 12-month price target, according to analysts?
Based on analyst ratings, Merck & Company’s 12-month average price target is 136.81.
    What is MRK’s upside potential, based on the analysts’ average price target?
    Merck & Company has 14.90% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is MRK a Buy, Sell or Hold?
          Merck & Company has a consensus rating of Moderate Buy which is based on 13 buy ratings, 6 hold ratings and 0 sell ratings.
            What is Merck & Company’s price target?
            The average price target for Merck & Company is 136.81. This is based on 19 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $179.00 ,the lowest forecast is $112.00. The average price target represents 14.90% Increase from the current price of $119.07.
              What do analysts say about Merck & Company?
              Merck & Company’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 19 Wall Streets Analysts.
                How can I buy shares of MRK?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.